0
Acute leukemia
- Dr Dinesh Bhurani, DM, FRCPA
Senior bone marrow transplant physician
Rajiv Gandhi Cancer Inst & RC, Delhi
ALL

CLL

Lymphomas

MM

naïve
B-lymphocytes

Lymphoid
progenitor

AML
Hematopoietic
stem cell

Myeloid
progenitor

Plasma...
Incidence
Acute myeloid leukaemia
ALL
Cytopenia
Production failure
• Stem cell defect
– Apastic anaemia

• Bone marrow
suppression
– Drugs
– Infections eg malaria, dengue...
Production failure
• Bone marrow infiltration
– Haematological malignancy
– Non haematological malignancy

• Marrow fibros...
Increased consumption

• Hypersplenism
• Immune cytopenia
Peripheral smear
• Oval macrocytes, hypersegmented neutrophils –
megaloblastic anaemia

• Leuko-erythroblastic blood pictu...
Leukaemia
• Pancytopenia or bicytopenia – Can it be
haematological malignancy? CBC &
peripheral smear
• Avoid steroids pri...
Bone marrow aspirate and
biopsy both are essential.
Acute Leukaemia
• Comprises approximately 30 percent of all childhood
malignancies
• An incidence of 2.8 cases per 100,000...
Acute leukaemia
• Persistent or progressive lymphadenopathy
that does not respond to antibiotic therapy
suggests the need ...
Differential diagnosis
•
•
•
•
•
•
•
•

Juvenile idiopathic arthritis
Osteomyelitis
Epstein-Barr virus
Idiopathic thromboc...
Acute lymphoblastic leukaemia
Etiology
Leukaemogenesis
Leukaemogenesis
Classification
Acute myeloid leukaemia
Diagnosis
Peripheral smear
Bone marrow
Cytochemistry
Flowcytometry
Cytogenetics
FISH
PCR
Prognosis
Prognostic factors
•
•
•
•
•

Age
Initial WBC count
Cytogenetics
Immunologic subtype
Response to initial therapy
Risk groups
•
•
•
•

Low risk — 92 percent
Standard risk — 82 percent
High risk — 73 percent
Very high risk — 46 percent
Acute lymphoid leukaemia
Acute myeloid leukaemia
Acute myeloid leukaemia
Acute myeloid leukaemia
Treatment
Acute lymphoblastic leukaemia
• INDUCTION THERAPY
– To eradicate more than 99 percent of the initial burden.
– to restore ...
Acute myeloid leukaemia
• Induction therapy
– Cytarabine (7 days) & Daunorubicine (3days)

• Consolidation therapy
– 3-4 c...
Acute myeloid leukaemia
Future
Minimal residual disease
Technique and criterion

Blasts per 100,000 nucleated cells

Standard microscopy ("complete
remis...
Upcoming SlideShare
Loading in...5
×

Acutelymphoblasticleukemia 120321114815-phpapp01(1)

296

Published on

Published in: Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
296
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Acutelymphoblasticleukemia 120321114815-phpapp01(1)"

  1. 1. Acute leukemia - Dr Dinesh Bhurani, DM, FRCPA Senior bone marrow transplant physician Rajiv Gandhi Cancer Inst & RC, Delhi
  2. 2. ALL CLL Lymphomas MM naïve B-lymphocytes Lymphoid progenitor AML Hematopoietic stem cell Myeloid progenitor Plasma cells T-lymphocytes Myeloproliferative disorders Neutrophils Eosinophils Basophils Monocytes Platelets Red cells
  3. 3. Incidence
  4. 4. Acute myeloid leukaemia
  5. 5. ALL
  6. 6. Cytopenia
  7. 7. Production failure • Stem cell defect – Apastic anaemia • Bone marrow suppression – Drugs – Infections eg malaria, dengue, HIV • Ineffective haemopoiesis – Megaloblastic anaemia – Myelodysplastic syndrome
  8. 8. Production failure • Bone marrow infiltration – Haematological malignancy – Non haematological malignancy • Marrow fibrosis – Primary – Secondary • Haemophagocytic syndrome
  9. 9. Increased consumption • Hypersplenism • Immune cytopenia
  10. 10. Peripheral smear • Oval macrocytes, hypersegmented neutrophils – megaloblastic anaemia • Leuko-erythroblastic blood picture – marrow infiltration • Leuko-erythroblastic picture with tear drop cells – marrow fibrosis • Blast or atypical lymphoid cells – haematological malignancy • Dysplastic feature – MDS, drugs or HIV infection
  11. 11. Leukaemia • Pancytopenia or bicytopenia – Can it be haematological malignancy? CBC & peripheral smear • Avoid steroids prior to confirmation of diagnosis
  12. 12. Bone marrow aspirate and biopsy both are essential.
  13. 13. Acute Leukaemia • Comprises approximately 30 percent of all childhood malignancies • An incidence of 2.8 cases per 100,000 • The peak incidence 2-5 Yrs • Studies of the relationship between childhood ALL, urban/rural status and population density, as well as other possible etiologic factors (eg, environmental exposures, abnormal immune response to common infections) have yielded inconsistent results
  14. 14. Acute leukaemia • Persistent or progressive lymphadenopathy that does not respond to antibiotic therapy suggests the need for more extensive evaluation.
  15. 15. Differential diagnosis • • • • • • • • Juvenile idiopathic arthritis Osteomyelitis Epstein-Barr virus Idiopathic thrombocytopenic purpura Pertussis, parapertussis Aplastic anemia Acute infectious lymphocytosis Other malignancies with bone marrow involvement (eg, neuroblastoma, retinoblastoma, rhabdomyosarcoma, and Ewing sarcoma
  16. 16. Acute lymphoblastic leukaemia
  17. 17. Etiology
  18. 18. Leukaemogenesis
  19. 19. Leukaemogenesis
  20. 20. Classification
  21. 21. Acute myeloid leukaemia
  22. 22. Diagnosis
  23. 23. Peripheral smear
  24. 24. Bone marrow
  25. 25. Cytochemistry
  26. 26. Flowcytometry
  27. 27. Cytogenetics
  28. 28. FISH
  29. 29. PCR
  30. 30. Prognosis
  31. 31. Prognostic factors • • • • • Age Initial WBC count Cytogenetics Immunologic subtype Response to initial therapy
  32. 32. Risk groups • • • • Low risk — 92 percent Standard risk — 82 percent High risk — 73 percent Very high risk — 46 percent
  33. 33. Acute lymphoid leukaemia
  34. 34. Acute myeloid leukaemia
  35. 35. Acute myeloid leukaemia
  36. 36. Acute myeloid leukaemia
  37. 37. Treatment
  38. 38. Acute lymphoblastic leukaemia • INDUCTION THERAPY – To eradicate more than 99 percent of the initial burden. – to restore normal hematopoiesis – Usually last for 4-5 weeks • Intensification (consolidation) therapy – High dose methotrexate – Reinduction therapy • CNS targeted therapy – Intrathecal chemo, cranial RT, High Mtx • Maintenance therapy – Oral 6MP and Mtx • Allogenic bone marrow transplantation
  39. 39. Acute myeloid leukaemia • Induction therapy – Cytarabine (7 days) & Daunorubicine (3days) • Consolidation therapy – 3-4 cycles of high dose cytarabine • Autologous and allogenic bone marrow transplantation
  40. 40. Acute myeloid leukaemia
  41. 41. Future
  42. 42. Minimal residual disease Technique and criterion Blasts per 100,000 nucleated cells Standard microscopy ("complete remission") 5,000 Karyotype analysis (20 mitotic figures) 5,000 Microscopy, expert 1,000 Immunophenotyping: multiparameter flow cytometry 10 Colony growth 1 Polymerase chain reaction 0.1
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×